Jubilant Pharmova Limited
NSE: JUBLPHARMA BSE: JUBLPHARMA
NSE
987.65
29.90 (3.12%)
Prev Close
957.75
Open Price
996
Volume
39,328
Today Low / High
965.5 / 998.35
52 WK Low / High
802 / 1248
Range
938 - 1,037
BSE
974.45
17.00 (1.78%)
Prev Close
957.45
Open Price
987.6
Volume
2,695
Today Low / High
967 / 998.75
52 WK Low / High
823.7 / 1250
Range
926 - 1,023
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 987.65 (target range: 938 - 1,037), reflecting a change of 29.9 (3.1219%). On the BSE, it is listed at 974.45 (target range: 926 - 1,023), showing a change of 17 (1.77555%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Feb
959.10
-0.14%
01 Feb
981.90
-1.43%
30 Jan
942.00
4.24%
29 Jan
965.00
-2.79%
28 Jan
940.90
2.26%
27 Jan
951.00
-1.27%
23 Jan
968.00
-1.23%
22 Jan
954.90
1.37%
21 Jan
942.20
0.49%
20 Jan
994.00
-4.35%
19 Jan
1,031.00
-3.54%
16 Jan
1,055.70
-0.96%
14 Jan
1,031.10
3.41%
13 Jan
1,044.00
-0.33%
12 Jan
1,063.00
-1.18%
09 Jan
1,074.50
-0.96%
08 Jan
1,078.00
-0.32%
07 Jan
1,073.40
0.43%
06 Jan
1,070.60
0.79%
Jubilant Pharmova Limited Graph
Jubilant Pharmova Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Jubilant Pharmova Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 987.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 974.45 | 984.19 | 885.78 - 1,082.61 |
| 993.94 | 795.15 - 1,192.73 | ||
| 1,003.68 | 702.58 - 1,304.79 | ||
| Bearish Scenario | 974.45 | 964.71 | 868.23 - 1,061.18 |
| 954.96 | 763.97 - 1,145.95 | ||
| 945.22 | 661.65 - 1,228.78 |
Overview of Jubilant Pharmova Limited
ISIN
INE700A01033
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
128,111
Market Cap
156,445,555,562
Last Dividend
5
Official Website
IPO Date
2002-07-01
DCF Diff
243.02
DCF
715
Financial Ratios Every Investor Needs
Stock Dividend of JUBLPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 5 | 5 | 2025-07-25 | 2025-09-28 | |
| 2024-08-02 | August 02, 24 | 5 | 5 | 2024-08-02 | 2024-09-29 | |
| 2023-08-10 | August 10, 23 | 5 | 5 | 2023-08-10 | 2023-09-30 | |
| 2022-08-11 | August 11, 22 | 5 | 5 | 2022-08-12 | 2022-10-25 | |
| 2021-08-05 | August 05, 21 | 5 | 5 | 2021-08-06 | 2021-10-20 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 7,234.50 Cr | 2,535.70 Cr | 4,698.80 Cr | 0.6495 | 0.00 Cr | 2,274.40 Cr | 2,355.70 Cr | 839.40 Cr | 52.98 | 1,047.70 Cr | 0.1160 |
| 2024-03-31 | 6,702.90 Cr | 2,351.30 Cr | 4,351.60 Cr | 0.6492 | 0.00 Cr | 2,220.90 Cr | 2,064.30 Cr | 77.10 Cr | 4.86 | 793.30 Cr | 0.0115 |
| 2023-03-31 | 6,281.70 Cr | 2,081.60 Cr | 4,200.10 Cr | 0.6686 | 0.00 Cr | 2,173.80 Cr | 1,985.00 Cr | -61.00 Cr | -3.83 | 646.30 Cr | -0.0097 |
| 2022-03-31 | 6,130.16 Cr | 1,488.00 Cr | 4,642.16 Cr | 0.7573 | 0.00 Cr | 2,047.89 Cr | 2,568.29 Cr | 413.94 Cr | 26.01 | 1,066.28 Cr | 0.0675 |
| 2021-03-31 | 6,098.54 Cr | 1,536.01 Cr | 4,562.52 Cr | 0.7481 | 0.00 Cr | 1,927.79 Cr | 2,618.56 Cr | 835.87 Cr | 36.05 | 1,467.62 Cr | 0.1371 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,088.80 Cr | 12,756.40 Cr | 6,517.80 Cr | 6,254.9000 Cr | 2,731.00 Cr | 1,642.20 Cr | 1,129.20 Cr | 5,168.20 Cr | 123.00 Cr | 1.20 Cr | 47.40 Cr | 2,164.6000 Cr |
| 2024-03-31 | 953.90 Cr | 11,548.50 Cr | 6,127.40 Cr | 5,433.9000 Cr | 3,664.00 Cr | 2,710.10 Cr | 1,303.80 Cr | 3,687.10 Cr | 86.50 Cr | 543.80 Cr | 42.20 Cr | 1,889.0000 Cr |
| 2023-03-31 | 1,013.92 Cr | 11,156.65 Cr | 5,764.86 Cr | 5,399.2800 Cr | 3,676.76 Cr | 2,662.84 Cr | 1,421.50 Cr | 3,365.12 Cr | 476.18 Cr | 268.51 Cr | 256.42 Cr | 1,772.4000 Cr |
| 2022-03-31 | 980.26 Cr | 9,990.87 Cr | 4,674.47 Cr | 5,318.5630 Cr | 3,192.00 Cr | 2,211.74 Cr | 1,286.08 Cr | 2,791.10 Cr | 90.20 Cr | 7.30 Cr | 238.60 Cr | 1,591.6010 Cr |
| 2021-03-31 | 501.96 Cr | 8,918.11 Cr | 4,176.59 Cr | 4,741.4860 Cr | 2,829.56 Cr | 2,331.63 Cr | 1,142.85 Cr | 2,575.19 Cr | 357.26 Cr | 7.57 Cr | 53.54 Cr | 1,048.8330 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,072.1000 Cr | 487.7000 Cr | -1,452.7000 Cr | -43.5000 Cr | 131.9000 Cr | 1,088.3000 Cr | -1,115.6000 Cr | 839.4000 Cr | -1,073.0000 Cr | -79.6000 Cr | 78.5000 Cr |
| 2024-03-31 | 971.3000 Cr | -607.9000 Cr | -432.5000 Cr | 73.6000 Cr | -57.5000 Cr | 956.4000 Cr | -897.7000 Cr | 77.1000 Cr | -20.4000 Cr | -79.8000 Cr | 90.8000 Cr |
| 2023-03-31 | 660.6700 Cr | -544.4100 Cr | -156.6900 Cr | -153.7800 Cr | 30.1000 Cr | 1,013.9200 Cr | -814.4500 Cr | 27.7800 Cr | 231.7000 Cr | -80.0610 Cr | -64.6800 Cr |
| 2022-03-31 | 837.5430 Cr | -380.3700 Cr | -32.5990 Cr | 237.5520 Cr | 481.8620 Cr | 983.8190 Cr | -599.9910 Cr | 630.4470 Cr | 242.1800 Cr | -80.0530 Cr | -95.6470 Cr |
| 2021-03-31 | 1,784.2650 Cr | -739.0140 Cr | -1,709.3860 Cr | 1,256.7710 Cr | -728.8570 Cr | 501.9570 Cr | -527.4940 Cr | 1,212.0100 Cr | -1,349.7390 Cr | -1.4750 Cr | 134.3210 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,966.40 Cr | 1,337.50 Cr | 628.90 Cr | 0.3198 | 236.60 Cr | 120.30 Cr | 7.59 | 345.40 Cr | 0.0612 |
| 2025-06-30 | 1,900.70 Cr | 618.20 Cr | 1,282.50 Cr | 0.6748 | 691.40 Cr | 102.90 Cr | 6.49 | 283.65 Cr | 0.0541 |
| 2025-03-31 | 1,928.80 Cr | 844.80 Cr | 1,084.00 Cr | 0.5620 | 418.20 Cr | 153.60 Cr | 9.71 | 309.58 Cr | 0.0796 |
| 2024-12-31 | 1,821.70 Cr | 574.40 Cr | 1,247.30 Cr | 0.6847 | 687.20 Cr | 100.90 Cr | 6.37 | 263.65 Cr | 0.0554 |
| 2024-09-30 | 1,752.30 Cr | 554.80 Cr | 1,197.50 Cr | 0.6834 | 633.20 Cr | 102.80 Cr | 6.47 | 289.05 Cr | 0.0587 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 623.20 Cr | 0.00 Cr | 623.20 Cr | 963.30 Cr | 1,228.40 Cr | 3,458.90 Cr | 5,893.50 Cr | 13,521.20 Cr | 6,949.50 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1,088.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -6,238.60 Cr |
| 2025-03-31 | 1,088.80 Cr | 0.00 Cr | 1,088.80 Cr | 892.60 Cr | 1,129.20 Cr | 3,577.20 Cr | 5,168.20 Cr | 12,756.40 Cr | 6,517.80 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1,077.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -5,927.00 Cr |
| 2024-09-30 | 1,076.90 Cr | 0.50 Cr | 1,077.40 Cr | 796.20 Cr | 1,161.50 Cr | 3,501.80 Cr | 4,265.90 Cr | 11,924.40 Cr | 5,997.40 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 102.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 153.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 100.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 102.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 482.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2010-11-25 | November 25, 10 | 21:20 |
| 2006-03-17 | March 17, 06 | 5:1 |
| 2004-03-12 | March 12, 04 | 8:5 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,682.70 | ₹4,037,360,954,019.00 | ₹2,175,122.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,244.50 | ₹1,657,718,547,810.00 | ₹98,152.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,042.00 | ₹1,367,996,468,480.00 | ₹159,874.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,224.00 | ₹1,019,063,464,560.00 | ₹528,921.00 |
| Lupin Limited | LUPIN | ₹2,169.00 | ₹990,797,031,000.00 | ₹204,948.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹900.35 | ₹905,962,772,897.00 | ₹271,538.00 |
| Mankind Pharma Limited | MANKIND | ₹2,122.90 | ₹876,343,887,349.00 | ₹63,792.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,230.40 | ₹714,618,316,939.00 | ₹978,482.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,667.50 | ₹677,634,637,500.00 | ₹34,484.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,964.00 | ₹554,242,388,876.00 | ₹162,495.00 |
| Laurus Labs Limited | LAURUSLABS | ₹981.65 | ₹529,950,213,720.00 | ₹735,288.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,450.20 | ₹367,921,856,944.00 | ₹22,979.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,793.20 | ₹348,970,184,957.00 | ₹14,592.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,896.40 | ₹304,248,934,000.00 | ₹55,916.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,514.10 | ₹287,031,782,814.00 | ₹46,641.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,359.00 | ₹220,826,857,671.00 | ₹314,141.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,670.50 | ₹216,762,500,000.00 | ₹3,564.00 |
| Eris Lifesciences Limited | ERIS | ₹1,423.60 | ₹193,918,366,028.00 | ₹40,260.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,510.00 | ₹173,331,800,390.00 | ₹33,838.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹989.10 | ₹156,643,517,747.00 | ₹39,283.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹789.85 | ₹155,255,383,491.00 | ₹36,998.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹848.30 | ₹151,938,902,721.00 | ₹280,562.00 |
| Cohance Lifesciences Limited | COHANCE | ₹384.50 | ₹147,097,065,330.00 | ₹110,639.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,841.60 | ₹139,983,139,354.00 | ₹33,193.00 |
| Granules India Limited | GRANULES | ₹567.25 | ₹137,653,829,151.00 | ₹190,121.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹946.40 | ₹116,157,350,400.00 | ₹28,498.00 |
| Viyash Scientific Limited | VIYASH | ₹214.98 | ₹93,775,471,074.00 | ₹766,380.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,247.00 | ₹87,096,957,354.00 | ₹9,080.00 |
| Strides Pharma Science Limited | STAR | ₹852.40 | ₹78,568,023,257.00 | ₹112,827.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹785.50 | ₹71,203,449,437.00 | ₹51,323.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹445.80 | ₹68,252,897,456.00 | ₹28,558.00 |
| FDC Limited | FDC | ₹380.50 | ₹61,949,236,962.00 | ₹42,113.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹297.35 | ₹58,156,252,988.00 | ₹194,189.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹139.17 | ₹45,163,669,402.00 | ₹1,180,523.00 |
| Innova Captab Limited | INNOVACAP | ₹728.45 | ₹41,685,499,530.00 | ₹27,907.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹397.55 | ₹36,284,388,500.00 | ₹90,829.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹325.30 | ₹35,446,400,705.00 | ₹46,236.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹674.65 | ₹34,217,644,188.00 | ₹24,730.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.85 | ₹32,494,660,900.00 | ₹92,987.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,963.50 | ₹32,474,355,953.00 | ₹9,519.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹302.00 | ₹30,285,316,812.00 | ₹34,224.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹396.05 | ₹27,884,197,288.00 | ₹19,688.00 |
Key Executives
Senior Vice President of Corporate Affairs
A. Srivastava
Gender: male
Year Born: 1946
Joint MD & Director
Arjun Shanker Bhartia
Gender: male
Year Born: 1987
CFO & Group Treasurer
Arun Kumar Sharma
Gender: male
Year Born: 1966
Executive VP & Chief of Manufacturing
Biswajit Mitra
Gender: male
Year Born: 1962
President of Life Science Chemicals
Chandan Singh Sengar
Gender: male
Year Born: 1964
Company Secretary & Compliance Officer
Naresh Kapoor
Gender: male
Year Born: 1974
Executive VP of Group Accounts
Prakash Chandra Bisht
Gender: male
Year Born: 1964
MD & Director
Priyavrat Bhartia
Gender: male
Year Born: 1976
Advisor
Rajagopal Sankaraiah
Gender: male
Year Born: 1959
Executive VP & Head of Legal
Sanjay Gupta
Gender: male
Year Born: 1966
Group Chief Human Resources Officer
Shantanu Jha
Gender: male
Year Born:
Senior VP and Business Unit Head of Ethanol & Speciality Gases
Vimal Deep Kulshrestha
Gender: male
Year Born: 1965
FAQs about Jubilant Pharmova Limited
Who is the CEO of the company?
The CEO is Priyavrat Bhartia.
What is the current market price of the stock?
The current price is ₹987.85.
What is the 52-week price range?
The range is ₹802-1248.
What is the market capitalization of the company?
The market capitalization is ₹15,644.56 crores.
What is the dividend yield?
The dividend yield is 0.51%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 32.76.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Jubilant Pharmova Limited (ISIN: INE700A01033) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹15,644.56 crores and an average daily volume of 128,111 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.